Influenza Treatment Market (By Treatment: Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate; By Route Of Administration; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The global influenza treatment market size was estimated at around USD 5.95 billion in 2023 and it is projected to hit around USD 6.71 billion by 2033, growing at a CAGR of 1.21% from 2024 to 2033.

Key Pointers

• North America dominated the market with the largest market share of 42% in 2023.
• By Treatment, the oseltamivir phosphate secured the largest market share 28% in 2023.
• By Route of Administration, the oral route segment had the largest market share of 70% in 2023.
• By Distribution Channel, the hospital pharmacies segment captured the maximum market share of 48% in 2023.

Influenza Treatment Market Overview

The influenza treatment market is a dynamic and critical segment within the pharmaceutical and healthcare industry. Influenza, commonly known as the flu, is a highly contagious respiratory illness caused by influenza viruses. As a result, the demand for effective treatments and therapeutics to manage and mitigate the impact of influenza remains a key focus area for pharmaceutical companies and healthcare providers.

Influenza Treatment Market Growth

The robust growth of the influenza treatment market can be attributed to several key factors. Firstly, ongoing advancements in medical research and technology contribute to the development of more effective antiviral medications and vaccines, enhancing the overall treatment landscape. Additionally, heightened awareness of influenza's potential severity, coupled with increasing initiatives for vaccination campaigns globally, fuels the demand for preventive measures. The ever-present threat of new influenza strains and the need for rapid response mechanisms stimulate continuous research and development, driving innovation within the market. Collaborations between pharmaceutical companies, government agencies, and research institutions play a pivotal role in accelerating treatment discoveries and ensuring widespread accessibility. Moreover, the market's resilience is fortified by the collective commitment to public health, resulting in a continuous evolution of strategies and products aimed at mitigating the impact of influenza. As these growth factors intertwine, the influenza treatment market is poised for sustained expansion in the foreseeable future.

Report Scope of the Influenza Treatment Market

Influenza Treatment Market Dynamics

Drivers

• Advancements in Antiviral Medications: Ongoing research and development efforts have led to the creation of more effective and targeted antiviral medications, enhancing the treatment options available for influenza.
• Global Vaccination Initiatives: Increasing awareness of the importance of influenza vaccination, coupled with extensive global vaccination campaigns, is a significant driver. This proactive approach toward prevention positively impacts the market by reducing the overall disease burden.

Restraints

• Vaccine Production Challenges: The complex nature of influenza viruses and the need for annual vaccine updates pose challenges in vaccine production. Delays in manufacturing processes can limit the timely availability of vaccines, impacting the overall efficacy of preventive measures.
• Antiviral Resistance: The emergence of antiviral resistance poses a significant restraint on influenza treatment. Continued use of certain antiviral medications may lead to the development of resistance, limiting the effectiveness of these drugs and necessitating the exploration of alternative treatment options.

Opportunities

• Advancements in Technology: The integration of cutting-edge technologies, such as artificial intelligence and machine learning, presents an opportunity to enhance the efficiency of influenza diagnosis, treatment monitoring, and drug discovery processes.
• Development of Universal Vaccines: Research and development efforts focused on creating universal influenza vaccines capable of providing broad-spectrum protection against various strains represent a significant opportunity. Such vaccines could revolutionize influenza prevention strategies.

Treatment Insights

The oseltamivir phosphate secured the largest market share 28% in 2023. Oseltamivir Phosphate, an antiviral drug approved for treating acute influenza in patients aged 2 weeks and older, is effective against Type A and B influenza. Its approval extends to both treatment and prevention within the community. Notably, in July 2020, Novadoz obtained FDA approval for a generic version of Tamiflu and introduced Tykosin. Tamiflu, available in various dosages (30 mg, 40 mg, and 75 mg), hinders influenza virus replication, reducing the severity and duration of flu symptoms when administered early in the illness. Consequently, these factors contribute significantly to the segment's growth.

Baloxavir marboxil is poised to exhibit the highest growth rate in the forecast period. This antiviral drug, approved by the U.S. FDA in 2018, is gaining traction for its oral administration in treating influenza. The increasing demand for baloxavir marboxil is expected to propel market growth, as it inhibits a distinct viral protein, the cap-dependent endonuclease, displaying efficacy against both influenza A and B viruses. Furthermore, its widespread adoption for influenza treatment has opened avenues for novel combination therapies, integrating medications with diverse mechanisms of action.

Route Of Administration Insights

The oral route segment had the largest market share of 70% in 2023. This prevalence is attributed to the widespread use of the oral route for drug administration, owing to its convenience, non-invasiveness, and high patient compliance. According to the National Center for Biotechnology Information (NCBI), approximately 60% of established drug products are commercially administered orally, representing a majority share across various pharmaceutical formulations for human medication. The oral drug category continues to evolve, offering the potential for positive patient outcomes. Moreover, the availability of diverse drugs, including Peramivir, Zanamivir, Baloxavir Marboxil, and Oseltamivir Phosphate in oral forms, has further fueled the demand for this administration route.

Additionally, the other segment is anticipated to experience the fastest growth rate during the forecast period. This growth is driven by an increased demand for parenteral and intravenous routes of administration, which offer heightened safety and efficacy in flu medication. According to NCBI, Peramivir, for instance, presents a single-dose intravenous (IV) treatment option for influenza, commonly employed in treating patients with complicated and high-risk influenza cases. Consequently, these factors contribute to the robust growth of the other route of administration segment.

Distribution Channel Insights

The hospital pharmacies segment captured the maximum market share of 48% in 2023. This dominance is primarily attributed to the escalating rates of hospitalizations and the growing demand for prescribed medications for treating influenza. Additionally, the majority of hospitals offer drugs at discounted prices, fostering widespread adoption of these medications. The proliferation of pharmacies within hospital and clinic settings has further propelled revenue growth, facilitated by an increased uptake of over-the-counter drugs. Consequently, this segment is poised to experience heightened demand for products throughout the forecast period.

Concurrently, the online pharmacies segment is projected to exhibit the fastest growth rate in the forecast period. This anticipation stems from the advantages of rapid access to medical products, privacy, cost efficiency, and the extensive availability of medicines, all from the comfort of one's home. Online pharmacies offer an efficient distribution channel, particularly beneficial for the elderly, disabled individuals, and those residing in remote locations, providing a convenient and swift avenue for obtaining necessary medications. Furthermore, the global pandemic has contributed to the increased adoption of online pharmacies due to restrictions on movement. The escalating internet penetration and the growing necessity for delivering medications to remote areas collectively propel the overall market growth.

Regional Insights

North America dominated the market with the largest market share of 42% in 2023. The region's robust performance is driven by factors such as an expanding population susceptible to respiratory illnesses, the continual rise of seasonal flu, increased hospitalization rates due to such conditions, and the presence of well-established healthcare facilities. The elevated risk of seasonal flu, especially among vulnerable populations like small children, the elderly, pregnant women, and healthcare workers, has propelled the demand for influenza treatment in the region. Seasonal flu, a prevalent health concern occurring typically between December and February, underscores the necessity for effective therapeutics. Key market players are strategically focusing on developing innovative therapeutics to address the growing prevalence of influenza. For instance, in August 2022, Genentech obtained supplemental New Drug Application approval for Xofluza, a treatment for uncomplicated acute influenza.

In contrast, Asia Pacific is poised to exhibit the fastest growth over the forecast period. This growth is attributed to the increasing elderly population in Asian countries, prone to respiratory conditions and supported by enhanced influenza surveillance practices in the region. Additionally, factors such as developing healthcare infrastructure, a robust presence of pharmaceutical companies, rising demand for influenza drugs, and improved control strategies collectively contribute to this growth trajectory. Regional players are actively introducing novel treatment options into the market. For example, in March 2023, TaiGen Biotechnology Co., Ltd. entered into a licensing agreement with Joincare Pharmaceutical Group Industry Co., Ltd. for the development and commercialization of TG-1000 in China, targeting infections caused by influenza-B, influenza-A, avian flu H7N9, and Tamiflu-resistant viruses.

Key Companies

• NATCO Pharma Limited
• Novartis AG
• F. Hoffmann-La Roche Ltd
• BioCryst Pharmaceuticals, Inc.
• Sanofi
• GSK plc.
• Viatris Inc. (MYLAN)
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company, Limited.
• AstraZeneca

Influenza Treatment Market Segmentations:

By Treatment

• Peramivir
• Zanamivir
• Baloxavir Marboxil
• Oseltamivir Phosphate
• Others

By Route of Administration

• Oral
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa